Memorial Sloan Kettering Cancer Center officials violated conflict of interest policies

pharmafile | April 5, 2019 | News story | Medical Communications, Research and Development Cancer, Memorial Sloan Kettering Cancer Center, oncology, research 

Top officials at the Memorial Sloan Kettering Cancer Center repeatedly violated policies on financial conflicts of interest, according to details from an outside review.

The top brass fostered a culture in which profits took precedence over research and patient care, the review, conducted by the law firm Debevoise & Plimpton, said.

The findings come after months of scrutiny over the cancer center’s executive’s financial ties to drug and health care firms.

The review found that officials frequently violated or skirted around their own policies; that links to companies were not vetted rigorously but instead came under scrutiny on an ad hoc basis; and that researchers were often unaware that senior executives had financial stakes in the outcomes of their studies.

The Cancer Center has acknowledged its oversights and announced an overhaul of conflict of interest policies.

Scott Stuart, chairman of the cancer center’s Boards of Overseers and Managers, commented in a statement to the New York Times: “We took a deep and honest look at what went wrong at our own institution, examined what was occurring in the wider cancer research community, and are putting in place best practices that will not only allow us to learn from our mistakes, but will contribute to best practices for the wider research community.”

The report comes after Dr José Baselga announced his resignation from his position as Physician-in-Chief at the Memorial Sloan Kettering Cancer Center after it was reported that the medical oncologist had failed to disclose multi-million dollar financial ties with pharmaceutical companies in September of 2018.

Louis Goss

Related Content


GRAIL and University of Oxford showcase first prospective study results for multi-cancer early detection test

US-based healthcare company GRAIL and the University of Oxford, UK, have announced encouraging first prospective …

ISA Pharmaceuticals highlights positive clinical data at ASCO

Clinical stage biotechnology company ISA Pharmaceuticals has announced positive phase 1 data at the American …

GSK receives FDA file acceptance for Jemperli plus chemotherapy for treating endometrial cancer

GSK has announced that the US Food and Drug Administration (FDA) has accepted the supplemental …

Latest content